Disparagement: The French Supreme Court rejects the appeal against the decision of the Paris Court of Appeal which had essentially confirmed the decision of the French Competition Authority to sanction a pharmaceutical company for abuse of a dominant position which delayed and then limited the development of generic medicines (Janssen-Cilag / Johnson & Johnson)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. In a ruling dated June 1, 2022, the Court of Cassation dismissed the appeal filed by the laboratory Janssen-Cilag and its parent company Johnson & Johnson [hereafter "Janssen- Cilag"] against the July 11, 2019 judgment of the Paris Court of Appeal, which had largely upheld the decision of the French Competition Authority [hereinafter "the Authority"] of December 20, 2017. By this decision of the Authority, Janssen-Cilag had been sanctioned for first delaying and then limiting the development of generics of its drug, Durogesic (Decision No. 17-D-25 of December 20, 2017 on practices implemented in the fentanyl transdermal device sector, Comm. A. Wachsmann,